Phase 2B VISUALIZE study results published in @AnnSurgOncol demonstrate abenacianine with intraoperative molecular imaging improved tumor visualization during lung cancer surgery. bit.ly/4c6Md5v #OncologyInnovation #ClinicalResearch

Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery. Read more: bit.ly/43kDXu7 #Leadership

#News: Vergent Bioscience has initiated VISUALIZE 2, a Phase 3 pivotal study evaluating abenacianine (VGT-309) for tumor visualization during lung cancer surgery. Read more: bit.ly/4lB9aS0 #OncologyInnovation #ClinicalResearch

Following #ASCO25, CEO @JSantini1 spoke with ONCOLife to discuss how abenacianine (VGT-309) is shining a light on #lungcancersurgery. ▶️ Watch: bit.ly/44M9vJv #Innovation #OncologyInnovation #Biotech #ThoracicSurgery

#News: Phase 2B VISUALIZE study results will be presented by @PennMedicine’s Dr. Sunil Singhal at #ASCO25, demonstrating that intraoperative molecular imaging with abenacianine for injection (VGT-309) during lung surgery has the potential to improve surgical outcomes. More: bit.ly/439aILt

#News: @PennMedicine’s Dr. Sunil Singhal will present new data from Vergent Bioscience on abenacianine (VGT-309) at #ASCO25, showcasing advances in tumor visualization with the potential to transform how surgeons identify and remove cancerous tissue. bit.ly/4jQ326I

Our CEO @JSantini1recently chatted with @MedTechGurus about Vergent’s mission and efforts to help surgeons unlock the full potential of minimally invasive and robotic-assisted surgery by making tumors easier to see. Learn more: bit.ly/3Y6hZZK #LCAM #Innovation

We were honored to join the 5th International Sublobar Resections & Bronchoscopic Ablation Summit last week in Paris! Engaging with global experts who are advancing #LungCancer care through innovation inspires us to continue working toward better surgical outcomes. #InnovationInMedicine

#NEWS: Vergent has received Fast Track designation from the @US_FDA for our novel, investigational tumor-targeted fluorescent imaging agent. Read more: bit.ly/4j3ZEFm #meded #lungcancer

Vergent is a proud sponsor of the 5th International Sublobar Resections and Bronchoscopic Ablation Summit, taking place January 9 & 10 in #Paris. We’re looking forward to connecting with global leaders and exploring the latest in surgical #innovation.

#DYK when #lungcancer is caught early, surgery can be an effective treatment? Our mission is to make #cancer surgery more successful by enhancing #tumorvisualization during surgery. Learn more in this recent @MedTechGurus episode: bit.ly/3Y6hZZK #Innovation

Approximately every 2.5 minutes, someone in the U.S. is diagnosed with lung cancer. During #LungCancerAwarenessMonth, we join the community in raising awareness of #LungCancer as one of the most common and deadly cancers. Learn more about our work: vergentbio.com/technology

We’ve completed patient enrollment in our Phase 2 VISUALIZE trial evaluating the potential of our novel, investigational tumor-targeted fluorescent imaging agent to improve tumor visualization during lung cancer surgery. Learn more: vergentbio.com/news-2024-nov… #clinicaltrials

At @WMISWMIC next week, @PennMedicine’s Dr. Sunil Singhal will share clinical research that shows how enhanced tumor visualization may benefit surgeons and patients during #lungcancer surgery. Learn more here: bit.ly/4e1KZHw #WMIC2024 #tumorvisualization #meded #MedX

Phase 2 data published in @STS_CTsurgery journal @annalsthorsurg show VGT-309 may help surgeons see difficult-to-find and previously undetected tumors in real-time during #MIS and robotic-assisted surgery. bit.ly/4bNYCIE #TumorVisualization #LungCancer

CEO @JSantini1 spoke with ONCOLife about our investigational advanced imaging agent, VGT-309. See how we’re enhancing tumor visualization & creating the potential to make cancer surgery more successful for both surgeons & patients. healthandpharma.net/oncolife (p42) #MedEd #Biotech

We're excited to welcome Alix Alderman to our #leadership team! A renowned global regulatory professional, her more than 20 years of drug development experience will help drive our mission to reimagine tumor visualization. bit.ly/49VZnyp #BioTech #TeamVergent

Thanks to @9NewsMelb for highlighting our study of VGT-309 with @StVincentsMelb, as we aim to help surgeons see difficult-to-find tumors in real time during surgery. Check out the story below! #lungcancer #innovation @msanto92

New data presented at the 60th Annual Meeting of the Society of Thoracic Surgeons demonstrate that VGT-309 helps surgeons visualize primary and metastatic tumor tissue in the lung during surgery. Learn more: vergentbio.com/vergent-prese… #STS2024 @STS_CTsurgery #lungcancer

#NEWS: The first patients have been enrolled in our Phase 2 multi-center VISUALIZE study! The study will assess the potential of our tumor-targeted fluorescent imaging agent, VGT-309, to improve visibility of tumors during lung cancer surgery. Read more: vergentbio.com/vergent-bio-i… #clinicaltrials #medtwitter #meded